DOCSLIB.ORG

Avelox 400 Mg Tablets Are Dull Red Oblong, Film-Coated, Convex Tablets Marked with M 400 on One Side and BAYER on the Other Side

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Avelox 400 Mg Tablets Are Dull Red Oblong, Film-Coated, Convex Tablets Marked with M 400 on One Side and BAYER on the Other Side ® AVELOX TABLETS (AV•e•lox) moxifloxacin hydrochloride Consumer Medicine Information for Avelox IV, you should read • swelling of the face, lips, WHAT IS IN THIS this leaflet as well as it contains tongue or other parts of the LEAFLET information specific to the body tablets. • rash, itching or hives on the This leaflet answers some skin common questions about Avelox Avelox tablets contain the active ingredient moxifloxacin, which Do not take this medicine if tablets. you are pregnant or think you is an antibiotic belonging to a group of medicines called might be pregnant. It does not contain all of the It may affect your developing available information. It does not fluoroquinolones. These antibiotics work by killing the baby if you take it during take the place of talking to your pregnancy. It is not known if it is doctor or pharmacist. bacteria that are causing your infection. safe for you to take Avelox tablets while you are pregnant. All medicines have risks and Avelox tablets will not work Drugs similar to Avelox have benefits. Your doctor has caused joint disease in immature weighed the risks of you taking against infections caused by viruses such as colds or the flu. animals. Tell your doctor if you Avelox against the benefits they are or may be pregnant. expect it will have for you. Avelox tablets are available by prescription only. Do not take this medicine if If you have any concerns about Ask your doctor if you have any questions about why this you are breastfeeding. taking this medicine, ask your Avelox is excreted in breast milk doctor or pharmacist. medicine has been prescribed for you. and there is a possibility that your baby may be affected. Your Keep this leaflet with the Your doctor may have prescribed it for another reason. doctor will tell you whether you medicine. should take Avelox and You may need to read it again. temporarily stop breastfeeding while you are taking the tablets. BEFORE YOU TAKE WHAT AVELOX IS AVELOX Do not give Avelox to children USED FOR under 18 years of age. When you must not take it Avelox tablets are used in adults Do not take Avelox if you: for the treatment of infections of Do not take Avelox tablets if • have a condition called the lungs, airways and sinuses. you have an allergy to: ‘QT prolongation’ which is • moxifloxacin, the active a type of abnormal heart In women Avelox tablets can be ingredient in Avelox rhythm • used to treat a condition called any of the ingredients listed • are taking medicines used pelvic inflammatory disease at the end of this leaflet to treat arrhythmia – fast, which is an infection of the • other medicines belonging to slow or irregular heart female upper genital tract. the quinolone family (e.g. beat (e.g. quinidine, ciprofloxacin, norfloxacin, procainamide, amiodarone, In certain infections, you may nalidixic acid) sotalol) require treatment with Avelox IV Some of the symptoms of an • have a blood test that injection followed by a course of allergic reaction may include: shows lower than normal Avelox tablets e.g. severe and • shortness of breath potassium levels complicated skin and skin • structure infections, complicated wheezing or difficulty breathing Do not take this medicine after abdominal infections. the expiry date printed on the Even if you have read the pack and blister. Consumer Medicine Information The expiry date is printed on the AVELOX® TABLETS NZ CMI – CCDS22 Page 1 of 5 carton and on each blister after If you have not told your • didanosine, a medicine used “EXP” (e.g. 11 18 refers to doctor about any of the above, to treat viral infections November 2018). The expiry tell him/her before you are You can still take these date refers to the last day of that given Avelox. medicines while you are taking month. If it has expired return it Avelox. However, you must to your pharmacist for disposal. Taking other medicines take Avelox at least 2 hours Tell your doctor if you are before, or 4 hours after taking Do not take this medicine if the taking any other medicines, any of these medicines to make packaging is torn or shows including those that you buy sure there is no problem with signs of tampering. absorption. If the packaging is damaged, without a prescription from return it to your pharmacist for your pharmacy, supermarket Your doctor or pharmacist will be disposal. or health food shop. able to tell you what to do when Avelox may have an effect on taking AVELOX with other If you are not sure whether the electro-cardiogram (ECG - medicines. you should start taking this an electrical record of the medicine, talk to your doctor. activity of the heart) and may add to the effect of other HOW TO TAKE Before you start to take it medicines on the ECG. You AVELOX Tell your doctor if you have should advise your doctor if you allergies to any other are taking any medicine that Follow all directions given to medicines, foods, preservatives might affect the heart rhythm. you by your doctor or or dyes. pharmacist carefully. In particular, tell your doctor if They may differ from the Tell your doctor if you: you are taking: information contained in this • or someone in your family • warfarin, a medicine used to leaflet. has a history of heart rhythm stop blood clots. Your doctor problems should perform INR testing If you do not understand the • are taking any medicine that and may adjust your warfarin instructions printed on the might affect heart rhythm dose pharmacist label, ask your (e.g. quinidine, procainamide, • medicines used to treat doctor or pharmacist for help. amiodarone, sotalol, abnormal heart rhythm (e.g. erythromycin, tricyclic quinidine, procainamide, How much to take antidepressants, amiodarone, sotalol) Your doctor or pharmacist will antipsychotics) • medicines that can affect the tell you how much and how • have low potassium levels heart rhythm (erythromycin, often you should take Avelox. • have had any condition tricyclic antidepressants, affecting the brain, antipsychotics) It is important that you take the particularly if you have ever • corticosteroids full course of treatment that your had a seizure (‘fit’) These medicines may affect each doctor has prescribed for you. • other or increase the chance of have severe liver problems • you getting a side effect. have a condition called The usual adult dosage for myasthenia gravis (a disease Avelox tablets for most Some medicines may interfere causing muscle weakness) infections is one 400 mg tablet with the absorption of Avelox • have or have had a mental once daily for 5 to 10 days. tablets. These medicines illness However, some types of include: • have diabetes infections may require longer • antacids, multivitamins, treatment. Your doctor will • have a history of tendon mineral supplements and determine the duration of time disease or disorder which was other medicines containing that you take the tablets related to treatment with iron, zinc, magnesium, depending on the type of fluoroquinolone antibiotics aluminium or calcium. infection you have. • • have ever been told that you sucralfate, a medicine used to have an aortic aneurysm treat duodenal or stomach You should not exceed the dose ulcers your doctor has prescribed for AVELOX® TABLETS NZ CMI – CCDS22 Page 2 of 5 you. The risk of heart rhythm Otherwise, take it as soon as you If you get diarrhoea, tell your problems may increase with an remember, and then go back to doctor or pharmacist increase of the dose. taking it as you would normally. immediately. Do this even if it occurs several How to take it Do not take a double dose to weeks after you have stopped make up for the dose that you taking Avelox. Diarrhoea may Swallow the tablet whole with missed. mean that you have a serious water. Do not chew the tablet. condition affecting your bowel. If you are not sure what to do, You may need urgent medical When to take it ask your doctor or pharmacist. care. Do not take any Avelox tablets are usually taken If you have trouble remembering medications for diarrhoea once a day. when to take your medicine, ask without checking with your your pharmacist for some hints. doctor. Take your tablet at the same time each day. It can be taken with or If you take too much Tell your doctor immediately if without food. It is advisable to (overdose) you feel any discomfort, pain, drink fluids liberally. swelling or inflammation of a Immediately telephone your tendon. doctor, or the Poisons Do not take Avelox at the same Medicines like Avelox have been Information Centre (New time as taking antacids reported to cause tendon damage Zealand: 0800 POISON or (containing magnesium, calcium, (especially the Achilles tendon). 0800 764 766), or go to the or aluminium), multivitamins This may occur even within the Accident and Emergency (containing iron or zinc), first 48 hours of treatment and up department at your nearest sucralfate (a medicine to treat to several months after hospital, if you think you or stomach ulcers) or didanosine (a completing treatment with anyone else may have taken medicine to treat viral Avelox. The risk of tendon too much Avelox. Do this even infections). damage may be increased in if there are no signs of elderly patients, during strenuous discomfort or poisoning. Taking these medicines at the physical activity, if you are You may need urgent medical same time as Avelox can currently being treated with a attention. interfere with the absorption of type of medicine called Avelox tablets and reduce their corticosteroids, if you have effectiveness in fighting the WHILE YOU ARE reduced kidney function or have infection.
Load more

Recommended publications
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Trend Analysis of Antibiotics Consumption Using WHO Aware Classification in Tertiary Care Hospital
    International Journal of Basic & Clinical Pharmacology Bhardwaj A et al. Int J Basic Clin Pharmacol. 2020 Nov;9(11):1675-1680 http:// www.ijbcp.com pISSN 2319-2003 | eISSN 2279-0780 DOI: https://dx.doi.org/10.18203/2319-2003.ijbcp20204493 Original Research Article Trend analysis of antibiotics consumption using WHO AWaRe classification in tertiary care hospital Ankit Bhardwaj*, Kaveri Kapoor, Vivek Singh Saraswathi institute of Medical Sciences, Pilakhuwa, Hapur, Uttar Pradesh, India Received: 21 August 2020 Accepted: 21 September 2020 *Correspondence: Dr. Ankit Bhardwaj, Email: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: Aim of the study was to assess trend in antibiotics consumption pattern from 2016 to 2019 using AWaRe classification, ATC and Defined daily dose methodology (DDD) in a tertiary care hospital. Antibiotics are crucial for treating infectious diseases and have significantly improved the prognosis of patients with infectious diseases, reducing morbidity and mortality. The aim of the study is to classify the antibiotic based on WHO AWaRe classification and compare their four-year consumption trends. The study was conducted at a tertiary care center, Pilakhuwa, Hapur. Antibiotic procurement data for a period of 4 years (2016-2019) was collected from the Central medical store. Methods: This is a retrospective time series analysis of systemic antibiotics with no intervention at patient level. Antibiotic procurement was taken as proxy for consumption assuming that same has been used.
    [Show full text]
  • Pharmacology-2/ Dr
    1 Pharmacology-2/ Dr. Y. Abusamra Pharmacology-2 Quinolones, trimethoprim & sulfonamides Dr. Yousef Abdel - Kareem Abusamra Faculty of Pharmacy Philadelphia University 2 3 LEARNING OUTCOMES After completing studying this chapter, the student should be able to: Classify the drugs into subgroups such as quinolones and sulfonamides. Recognize the bacterial spectrum of all these antibiotic and antibacterial groups. Summarize the most remarkable pharmacokinetic features of these drugs. Numerate the most important side effects associated with these agents. Select the antibiotic of choice to be used in certain infections, as associated with the patient status including comorbidity, the species of bacteria causing the infection and concurrently prescribed drugs. Reason some remarkable clinical considerations related to the use or contraindication or precaution of a certain drug. Illustrate the mechanism of action of each of these drugs. • Following synthesis of na lidixic a c id in the early 1960s, continued modification of the quinolone nucleus expanded the spectrum of activity, improved pharmacokinetics, and stabilized compounds against common mechanisms of resistance. • Overuse resulted in rising rates of resistance in gram-negative and gram-positive organisms, increased frequency of Clostridium difficile infections, and identification of numerous tough adverse effects. • Consequently, these agents have been relegated to second-line options for various indications. 4 Pharmacology-2/ Dr. Y. Abusamra Only will be mentioned here 5 Pharmacology-2/ Dr. Y. Abusamra Most bacterial species maintain two distinct type II topoisomerases that assist with deoxyribonucleic acid Topoisomerases: Supercoiling Unwinding (DNA) replication: . DNA gyrase {supercoiling} and . Topoisomerase IV {Unwinding}. Following cell wall entry through porin channels, fluoroquinolones bind to these enzymes and interfere with DNA ligation.
    [Show full text]
  • < INVENTED NAME > See Annex1 Film-Coated Tablet 2. Q
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT < INVENTED NAME > see annex1 film-coated tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 Film-coated tablet contains 400 mg norfloxacin. Excipient with known effects Each film-coated tablet contains 0.5 mg sunset yellow (E110) and 3.36 mg sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet Round, orange film-coated tablet, with an engraved line on one side. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications < INVENTED NAME > is indicated for the treatment of the following infections caused by norfloxacin-susceptible bacteria (see sections 4.2 and 5.1): Uncomplicated acute cystitis. In uncomplicated acute cystitis < INVENTED NAME > should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections. Urethritis including cases due to susceptible Neisseria gonorrhoeae Complicated urinary tract infections (except complicated pyelonephritis) Complicated acute cystitis Consideration should be given to official guidance on the appropriate use of antibacterial agents. 4.2 Posology and method of administration Posology The dosage depends on the susceptibility of the pathogens and severity of the disease, see recommended dosage in the table below. Susceptibility of the causative organism to the treatment should be tested (if possible), although therapy may be initiated before the results are available. In case of suspected failure of therapy, microbiological investigation for possible bacterial resistance should be undertaken.
    [Show full text]
  • Effects of Norfloxacin and Rifampicin on Growth and Streptolysin S Production in Hemolytic Streptococci
    Effects of Norfloxacin and Rifampicin on Growth and Streptolysin S Production in Hemolytic Streptococci Akira Taketo Department of Biochemistry I, Fukui Medical School, Matsuoka, Fukui 910—11, Japan and Yoriko Taketo Department of Pharmacology, School of Medicine, Kanazawa University, Kanazawa Ishikawa 920, Japan Z. Naturforsch. 40c, 647—651 (1985); received April 19/May 28, 1985 Streptolysin S, Norfloxacin, Rifampicin, Streptococcus pyogenes Norfloxacin, a nalidixic acid analogue, inhibited streptolysin S (SLS) production when added to young streptococcal culture. DNA synthesis was mainly affected, but increment of cell mass, RNA and protein was also significantly reduced in streptococci treated with norfloxacin. In stationary phase cells and in the washed resting bacteria, the toxin production was resistant to the drug. Pretreatment with norfloxacin did not abolish the cellular capacity to produce SLS. Al­ though extracellular SLS was detectable at log phase of streptococcal growth, enhanced produc­ tion of the toxin occurred upon cessation of coccal multiplication. In contrast to norfloxacin, lower concentration of rifampicin inhibited SLS production, even added at late log or early stationary phase. Roles of growth phase, medium and carrier in induction of SLS production were analyzed as well. Introduction synthesis by the carrier is deficient, although RNA or oligonucleotide added as the carrier for SLS is often Streptococcal growth and SLS production are not designated as “inducer”. affected by nalidixic acid [1], an inhibitor of DNA In order to address these questions, effects of in­ gyrase. The toxin production, which requires certain hibitors of nucleic acid synthesis have been tested, carrier substance such as RNA [2] or detergent [3], is and influences of culture conditions such as carrier insensitive to novobiocin as well [1], and possible supplementation and medium shift have been ex­ role of DNA gyrase in SLS messenger RNA syn­ amined, on macromolecular synthesis or SLS-pro- thesis remains to be elucidated.
    [Show full text]
  • Trends in Antibiotic Utilization in Eight Latin American Countries, 1997–2007
    Investigación original / Original research Trends in antibiotic utilization in eight Latin American countries, 1997–2007 Veronika J. Wirtz,1 Anahí Dreser,1 and Ralph Gonzales 2 Suggested citation Wirtz VJ, Dreser A, Gonzales R. Trends in antibiotic utilization in eight Latin American Countries, 1997–2007. Rev Panam Salud Publica. 2010;27(3):219–25. ABSTRACT Objective. To describe the trends in antibiotic utilization in eight Latin American countries between 1997–2007. Methods. We analyzed retail sales data of oral and injectable antibiotics (World Health Or- ganization (WHO) Anatomic Therapeutic Chemical (ATC) code J01) between 1997 and 2007 for Argentina, Brazil, Chile, Colombia, Mexico, Peru, Uruguay, and Venezuela. Antibiotics were aggregated and utilization was calculated for all antibiotics (J01); for macrolides, lin- cosamindes, and streptogramins (J01 F); and for quinolones (J01 M). The kilogram sales of each antibiotic were converted into defined daily dose per 1 000 inhabitants per day (DID) ac- cording to the WHO ATC classification system. We calculated the absolute change in DID and relative change expressed in percent of DID variation, using 1997 as a reference. Results. Total antibiotic utilization has increased in Peru, Venezuela, Uruguay, and Brazil, with the largest relative increases observed in Peru (5.58 DID, +70.6%) and Venezuela (4.81 DID, +43.0%). For Mexico (–2.43 DID; –15.5%) and Colombia (–4.10; –33.7%), utilization decreased. Argentina and Chile showed major reductions in antibiotic utilization during the middle of this period. In all countries, quinolone use increased, particularly sharply in Venezuela (1.86 DID, +282%). The increase in macrolide, lincosaminde, and streptogramin use was greatest in Peru (0.76 DID, +82.1%), followed by Brazil, Argentina, and Chile.
    [Show full text]
  • Disabling and Potentially Permanent Side Effects Lead to Suspension Or Restrictions of Quinolone and Fluoroquinolone Antibiotics
    11 March 2019 EMA/175398/2019 Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics On 15 November 2018, EMA finalised a review of serious, disabling and potentially permanent side effects with quinolone and fluoroquinolone antibiotics given by mouth, injection or inhalation. The review incorporated the views of patients, healthcare professionals and academics presented at EMA’s public hearing on fluoroquinolone and quinolone antibiotics in June 2018. EMA’s human medicines committee (CHMP) endorsed the recommendations of EMA’s safety committee (PRAC) and concluded that the marketing authorisation of medicines containing cinoxacin, flumequine, nalidixic acid, and pipemidic acid should be suspended. The CHMP confirmed that the use of the remaining fluoroquinolone antibiotics should be restricted. In addition, the prescribing information for healthcare professionals and information for patients will describe the disabling and potentially permanent side effects and advise patients to stop treatment with a fluoroquinolone antibiotic at the first sign of a side effect involving muscles, tendons or joints and the nervous system. Restrictions on the use of fluoroquinolone antibiotics will mean that they should not be used: to treat infections that might get better without treatment or are not severe (such as throat infections); to treat non-bacterial infections, e.g. non-bacterial (chronic) prostatitis; for preventing traveller’s diarrhoea or recurring lower urinary tract infections (urine infections that do not extend beyond the bladder); to treat mild or moderate bacterial infections unless other antibacterial medicines commonly recommended for these infections cannot be used. Importantly, fluoroquinolones should generally be avoided in patients who have previously had serious side effects with a fluoroquinolone or quinolone antibiotic.
    [Show full text]
  • First Order Derivative Spectrophotometric Method for Simultaneous Estimation of Metronidazole and Norfloxacin in Their Combined Dosage Form
    International Journal of Applied and Natural Sciences (IJANS) ISSN(P): 2319-4014; ISSN(E): 2319-4022 Vol. 2, Issue 5, Nov 2013, 21-26 © IASET FIRST ORDER DERIVATIVE SPECTROPHOTOMETRIC METHOD FOR SIMULTANEOUS ESTIMATION OF METRONIDAZOLE AND NORFLOXACIN IN THEIR COMBINED DOSAGE FORM RAJYA LAKSHMI CH1 & RAMBABU C2 1Department of Chemistry, Vishnu Institute of Technology, Bhimavaram, Andhra Pradesh, India 2Department of Chemistry, Acharya Nagarjuna University, Guntur, Andhra Pradesh, India ABSTRACT Derivative spectroscopy offers a useful approach for the analysis of drugs in mixtures. In this study First order derivative spectrophotometric method was developed for the simultaneous determination of Metronidazole (MET) and Norfloxacin (NOR) in bulk and combined tablet dosage form. The derivative spectra for both the methods were obtained in methanol and the linearity was obtained in the concentration range of 1.25 – 6.25 µg/ml for Metronidazole and 1.0 - 5.0µg/ml for Norfloxacin. The zero order spectra are obtained at wavelengths 311nm for Metronidazole and 283nm for Norfloxacin. First order derivative spectrophotometric method was based on the determination of both the drugs at their respective zero crossing point (ZCP). The determinations were made at 216 nm (ZCP of Norfloxacin) for Metronidazole and 209 nm (ZCP of Metronidazole) for Norfloxacin. The mean recovery was 99.8 and 100.7 for Metronidazole and Norfloxacin respectively. The method was found to be simple, sensitive, accurate and precise and was applicable for the simultaneous determination of Metronidazole and Norfloxacin in pharmaceutical tablet dosage form. The results of analysis have been validated statistically and by recovery studies. KEYWORDS: Metronidazole, Norfloxacin, Zero Order Spectra, First Order Spectra, Zero Crossing Point Validation INTRODUCTION Metronidazole (MET), chemically known as 2-(2-methyl-5-nitro-1H- imidazol-1-yl) ethanol (figure 1) is an antibiotic, antiprotozoal, amoebicidal, bactericidal and trichomonicidal.
    [Show full text]
  • Pharmacogenomic Associations Tables
    Pharmacogenomic Associations Tables Disclaimer: This is educational material intended for health care professionals. This list is not comprehensive for all of the drugs in the pharmacopeia but focuses on commonly used drugs with high levels of evidence that the CYPs (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4 and CYP3A5 only) and other select genes are relevant to a given drug’s metabolism. If a drug is not listed, there is not enough evidence for inclusion at this time. Other CYPs and other genes not described here may also be relevant but are out of scope for this document. This educational material is not intended to supersede the care provider’s experience and knowledge of her or his patient to establish a diagnosis or a treatment plan. All medications require careful clinical monitoring regardless of the information presented here. Table of Contents Table 1: Substrates of Cytochrome P450 (CYP) Enzymes Table 2: Inhibitors of Cytochrome P450 (CYP) Enzymes Table 3: Inducers of Cytochrome P450 (CYP) Enzymes Table 4: Alternate drugs NOT metabolized by CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4 or CYP3A5 enzymes Table 5: Glucose-6-Phosphate Dehydrogenase (G6PD) Associated Drugs and Compounds Table 6: Additional Pharmacogenomic Genes & Associated Drugs Table 1: Substrates of Cytochrome P450 (CYP) Enzymes Allergy Labetalol CYP2C19 Immunosuppressives Loratadine CYP3A4 Lidocaine CYP1A2 CYP2D6 Cyclosporine CYP3A4/5 Analgesic/Anesthesiology CYP3A4/5 Sirolimus CYP3A4/5 Losartan CYP2C9 CYP3A4/5 Codeine CYP2D6 activates Tacrolimus CYP3A4/5 Lovastatin
    [Show full text]
  • Fluoroquinolone Use in Paediatrics: Focus on Safety and Place in Therapy
    18th Expert Committee on the Selection and Use of Essential Medicines (2011) Fluoroquinolone Use in Paediatrics: Focus on Safety and Place in Therapy Jennifer A. Goldman, M.D. 1,2, Gregory L. Kearns, Pharm.D., Ph.D. 1,3,4 Departments of Pediatrics 1 and Pharmacology 3, University of Missouri – Kansas City and the Divisions of Pediatric Infectious Disease 2 and Clinical Pharmacology and Medical Toxicology, 4 Children’s Mercy Hospital, Kansas City, MO, USA Commissioned work for the Guidelines Group for the Revision of the “Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children”, World Health Organization, 30-31 March 2010, Geneva, Switzerland 1 I. Introduction The first quinolone, nalidixic acid, was developed in the 1960s and was used (off- label) in pediatric therapeutics without restriction. Consequent to their broad spectrum of antimicrobial (including anti-mycobacterial) effect and perceived excellent safety profile, there was considerable hope and expectation that this class of antibiotics would find an important place in pediatric therapeutics. However, reports of quinolone-associated injury in weight bearing joints of juvenile animals resulted not only in an apparent contraindication to their use in human infants and children but also, completely derailed their formal development by pharmaceutical companies for use in pediatrics. While this situation resulted from a genuine concern for safety seemingly supported by relevant experimental findings, it served initially to remove a potentially useful
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]
  • Noroxin® (Norfloxacin)
    TABLETS NOROXIN® (NORFLOXACIN) WARNING: Fluoroquinolones, including NOROXIN®, are associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is further increased in older patients usually over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants (See WARNINGS). To reduce the development of drug-resistant bacteria and maintain the effectiveness of NOROXIN∗ and other antibacterial drugs, NOROXIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION NOROXIN (Norfloxacin) is a synthetic, broad-spectrum antibacterial agent for oral administration. Norfloxacin, a fluoroquinolone, is 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3­ quinolinecarboxylic acid. Its empirical formula is C H FN O and the structural formula is: 16 18 3 3 Norfloxacin is a white to pale yellow crystalline powder with a molecular weight of 319.34 and a melting point of about 221°C. It is freely soluble in glacial acetic acid, and very slightly soluble in ethanol, methanol and water. NOROXIN is available in 400-mg tablets. Each tablet contains the following inactive ingredients: cellulose, croscarmellose sodium, hydroxypropyl cellulose, hydroxypropyl methylcellulose, magnesium stearate, and titanium dioxide. Norfloxacin, a fluoroquinolone, differs from non-fluorinated quinolones by having a fluorine atom at the 6 position and a piperazine moiety at the 7 position. CLINICAL PHARMACOLOGY In fasting healthy volunteers, at least 30-40% of an oral dose of NOROXIN is absorbed. Absorption is rapid following single doses of 200 mg, 400 mg and 800 mg.
    [Show full text]